Bioxodes’ antithrombotic meets development milestones - Company to launch Series A investment round to bring product to the clinic

Marche-en-Famenne, Belgium – Bioxodes SA, the Belgian-based start-up developing pharmaceutical products derived from natural sources, announces that it has successfully broug...
Read more



Bioxodes raises EUR 2.6 million ($ 3.5 million) to develop antithrombotic peptide derived from tick saliva

Marche-en-Famenne, Belgium, November 26, 2013 – Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million ($ 3.5 million) first seed funding rou...
Read more



Newly-Created Company, Bioxodes, Focused on Peptide Therapeutics from Natural Sources - June 2012

BELGIUM – Bioxodes, a new biotech start-up based in Belgium, today announced the completion of licensing discussions with the University of Brussels (ULB) in relation to a portfolio of patent...
Read more